Article

A Metaanalysis of the Effectiveness and Safety of Ozone Treatments for Herniated Lumbar Discs

ActiveO, Salt Lake City, Utah, USA.
Journal of vascular and interventional radiology: JVIR (Impact Factor: 2.15). 02/2010; 21(4):534-48. DOI: 10.1016/j.jvir.2009.12.393
Source: PubMed

ABSTRACT To determine statistically significant effects of oxygen/ozone treatment of herniated discs with respect to pain, function, and complication rate.
Random-effects metaanalyses were used to estimate outcomes for oxygen/ozone treatment of herniated discs. A literature search provided relevant studies that were weighted by a study quality score. Separate metaanalyses were performed for visual analog scale (VAS), Oswestry Disability Index (ODI), and modified MacNab outcome scales, as well as for complication rate. Institutional review board approval was not required for this retrospective analysis.
Twelve studies were included in the metaanalyses. The inclusion/exclusion criteria, patient demographics, clinical trial rankings, treatment procedures, outcome measures, and complications are summarized. Metaanalyses were performed on the oxygen/ozone treatment results for almost 8,000 patients from multiple centers. The mean improvement was 3.9 for VAS and 25.7 for ODI. The likelihood of showing improvement on the modified MacNab scale was 79.7%. The means for the VAS and ODI outcomes are well above the minimum clinically important difference and the minimum (significant) detectable change. The likelihood of complications was 0.064%.
Oxygen/ozone treatment of herniated discs is an effective and extremely safe procedure. The estimated improvement in pain and function is impressive in view of the broad inclusion criteria, which included patients ranging in age from 13 to 94 years with all types of disc herniations. Pain and function outcomes are similar to the outcomes for lumbar discs treated with surgical discectomy, but the complication rate is much lower (<0.1%) and the recovery time is significantly shorter.

2 Followers
 · 
135 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Coronary artery disease (CAD) is the most common cause of sudden death, and death of people over 20 years of age. Because ozone therapy can activate the antioxidant system and improve blood circulation and oxygen delivery to tissue, the aim of this study was to investigate the therapeutic efficacy of ozone in patients with CAD, treated with antithrombotic therapy, Aspirin and policosanol. A randomized controlled clinical trial was performed with 53 patients divided into two groups: one (n=27) treated with antithrombotic therapy and other (n=26) treated with antithrombotic therapy plus rectal insufflation of O(3). A parallel group (n=50) age and gender matched was used as reference for the experimental variables. The efficacy of the treatments was evaluated by comparing hemostatic indexes and biochemical markers of oxidative stress in both groups after 20 day of treatment. Ozone treatment significantly (P<0.001) improved prothrombin time when compared to the antithrombotic therapy only group, without modifying bleeding time. Combination antithrombotic therapy+O(3) improved the antioxidant status of patients reducing biomarkers of protein and lipid oxidation, enhancing total antioxidant status and modulating the level of superoxide dismutase and catalase with a 57% and 32% reduction in superoxide dismutase and catalase activities respectively, moving the redox environment to a status of low production of O(2)(•-) with an increase in H(2)O(2) detoxification. No side effects were observed. These results show that medical ozone treatment could be a complementary therapy in the treatment of CAD and its complications.
    European journal of pharmacology 07/2012; 691(1-3):156-62. DOI:10.1016/j.ejphar.2012.07.010 · 2.68 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: ObjectiveWe performed a retrospective study to evaluate the safety and effectiveness of ozone discolysis in sciatica due to a contained herniated disc.Material and methodThis study included 100 patients with symptoms of intense lumbosciatic pain, visual analog scale (VAS) > 6 and onset more than 3 months previously, who were unresponsive to analgesics and systemic corticosteroids for a minimum period of 1 month and who showed signs of radicular pain and radiation to the affected dermatome. The radiological inclusion criteria consisted of magnetic resonance imaging (MRI) evidence of a contained herniated disc. The treatment applied consisted of the following: a first session with epidural administration of 10 ml of ozone at 30 μg/ml, 4 mg of triamcinolone and 5 ml of bupivacaine 0.25% plus paravertebral administration of 10 ml of O3 at 30 μg/ml, 4 mg of triamcinolone and 5 ml bupivacaine 0.25% on the affected side; a second session between 7 and 10 days after the first, consisting of the same treatment; and a third session with intradiscal administration of 10-20 ml of O3 at 50 μg/ml plus prophylactic antibiotic therapy. Analgesic efficacy was evaluated at 1, 3, 6, 12 and 24 months through VAS and radiological evaluation with MRI at 3, 12 and 24 months. A result was considered: a) excellent when the patient was asymptomatic and able to fully return to work and resume physical exercise and VAS decreased > 70%; b) good when the patient had occasional back or sciatic pain, with complete return to work, occasional use of analgesics and VAS decreased > 40%, and c) poor when there was insufficient symptom improvement, daily medication intake, limitation of physical activity, change of work and VAS decreased by > 40%. P values of < 0.05 were considered significant.ResultsOf the 100 patients, 91 could be evaluated at 24 months (52 men and 39 women). Age ranged from 26 to 77 years with a mean age of 52+7 years. By order of frequency, the vertebrae affected were L4-L5 (49%), L5-S1 (41%), L3-L4 (9%), other vertebrae (11%). By month, an excellent result was obtained in the following percentages of patients: 1 month 95.6%; 3 months 91.3%; 6 months 90.7%; 12 months 87.7%; 2 and 24 months 81.1%. MRI showed a significant reduction in hernia volume in 79% of the patients. A second discolysis was required by five patients who were excluded from the study. There was one case of discitis and 11 cases of postpuncture headache (all in patients with L5-S1 discolysis) and four cases of lumbar pain requiring analgesic treatment. Thirty-two percent of the patients took paracetamol irregularly for lumbar pain. Patients requiring other types of medication were withdrawn from the study.ConclusionsIntradiscal ozone administration in the protocol described achieved early onset of pain reduction, which was maintained for more than 2 years, as well as a sustained reduction in hernia size produced by ozone.
    Revista de la Sociedad Española del Dolor 04/2009; DOI:10.1016/S1134-8046(09)71006-7
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this paper is to analyze why ozone can be medically useful when it dissolves in blood or in other biological fluids. In reviewing a number of clinical studies performed in Peripheral Arterial Diseases (PAD) during the last decades, it has been possible to confirm the long-held view that the inverted U-shaped curve, typical of the hormesis concept, is suitable to represent the therapeutic activity exerted by the so-called ozonated autohemotherapy. The quantitative and qualitative aspects of human blood ozonation have been also critically reviewed in regard to the biological, therapeutic and safety of ozone. It is hoped that this gas, although toxic for the pulmonary system during prolonged inhalation, will be soon recognized as a useful agent in oxidative-stress related diseases, joining other medical gases recently thought to be of therapeutic importance. Finally, the elucidation of the mechanisms of action of ozone as well as the obtained results in PAD may encourage clinical scientists to evaluate ozone therapy in vascular diseases in comparison to the current therapies.
    Journal of Translational Medicine 05/2011; 9:66. DOI:10.1186/1479-5876-9-66 · 3.99 Impact Factor